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Suppression of antidiuretic hormone secretion by clonidine in
the anesthetized dog. 5tudies were performed to determine the
mechanism by which the antihypertensive agent clonidine
increases urine flow (V). In 11 anesthetized, hydropenic dogs, i.v.
administration of clonidine (30 gJkg) increased arterial pressure
from 128±4 to 142±3 mm Hg and slowed heart rate from
138±7 to 95±7 beats/mm within 30 mm of injection; blood
pressure then fell to 121 5 mm Hg 30 to 60 mm after injection,
and 112 5 mm Hg in the next 30-mm period. V increased from
0.36±0.09 to 0.93±0.13 mI/mm and urine osmolality (Uo,m)
decreased from 1378±140 to 488±82 mOsm/kg of H20 30 to
60 mm following injection (P<0.001). These changes were
accompanied by a decrease in T°H2O. This increased V was not
associated with increased glomerular filtration rate (GFR) or
solute excretion, and occurred in acutely denervated kidneys and
kidneys protected from the initial increase in arterial pressure by
constriction of a suprarenal aortic clamp. By contrast, V,
TCH2O and Uo,m were not altered by clonidine administration in
seven acutely hypophysectomized dogs receiving a constant
infusion of antidiuretic hormone (ADH) (80 1LU/kg/min),
despite similar hemodynamic changes produced by the drug.
The results suggest that clonidine increases V through inhibition
of ADH release, possibly via an indirect pathway mediated by
the drug's aipha-adrenergic effects on the circulation.
Suppression de Ia secretion d'hormone antidiurétique par Ia
clonidine chez le chien anesthésié. Ce travail a été entrepris pour
determiner le mécanisme par lequel Ia clonidine, agent hypo-
tenseur, augmente Ic debit urinaire (V). Chez 11 chiens anes-
thésiés, hydropéniques, Ia clonidine intraveineuse (30 pg/kg)
fait augmenter Ia pression artérielle de 128 4 a 142 3 mm Hg
et ralentit le rythme cardiaque de 138±7 a 95±7 battements/
minute dans les 30 mm qui suivent l'injection, puis Ia pression
artérielle chute a 121 5 mm Hg 30 a 60 mm apre l'injection et a
112±5 mm Hg dans les 30 mm suivantes. V augmente de
0,36 0,09 a 0,93 0,13 mI/mm et l'osmolalité urinaire (Vo,m)
diminue de 1378± 140 a 488±82 mOsm/kg H20 30 a 60 mm
aprés l'injection (P< 0,001). Ces modifications sont accom-
pagnées par une diminution de TCH2O. L'augmentation de V
n'est pas associée it une augmentation de GFR ou de I'excrétion
de substances dissoutes et survient aussi bien quand les reins
sont dénervCs de facon aigue ou quand ils sont protégés de
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l'augmentation initiale de Ia pression artérielle par une constric-
tion aortique sus-rénale. Au contraire, V, Tc2o et Vosm ne sont
pas modifies par Ia clonidine administrée a sept chiens hypo-
physectomisés qui recoivent une perfusion constante d'ADH
(80 1LU/kg/min), malgré des modifications hémodynamiques
semblables. Les résultats suggCrent que Ia clonidine augmente V
par l'inhibition de Ia liberation d'ADH, peut-être par une voie
indirecte empruntant les affets alpha adrCnergiques de Ia
drogue sur Ia circulation.
The imidazoline derivative clonidine (2-(2,6-dichlor-
phenylamino)-2-imidazoline hydrochloride) is a
sympathomimetic agent with marked cardiovascular
effects. It has proved of value in clinical medicine as
an orally administered hypotensive agent [1—3]; it
lowers mean arterial pressure through inhibition of
central vasomotor and cardiac centers [4—7]. When
administered i.v., it produces a transient increase in
blood pressure, before its more sustained hypotensive
effects are noted [4]. It also causes renal vasoconstric-
tion and may decrease sodium excretion [3], and in
addition has been noted to increase urine flow in
anesthetized dogs [8, 9] and rats [10]. It is known that
norepinephrine increases renal water excretion by
inhibiting antidiuretic hormone (ADH) secretion
[11, 12] and since clonidine shares many cc-adrenergic
stimulating properties with norepinephrine, it seemed
possible that a similar mechanism could explain the
increase in urine flow following clonidine administra-
tion. Studies were consequently undertaken to examine
this possibility. It was found that clonidine increased
urine flow and decreased urinary osmolality and solute-
free water reabsorption when given i.v. to intact,
hydropenic dogs, but not when given to acutely
hypophysectomized animals receiving a constant
infusion of ADH. These findings indicate that clonidine
suppresses the release of ADH, and thus increases
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water excretion by the same mechanism as norepine-
phrine.
Methods
Studies were performed in 20 male mongrel dogs
weighing between 15.2 and 25.6 kg which had been
fasted for 24 hr prior to the experiment but allowed
free access to water. The animals were anesthetized
with sodium pentobarbital (30 mg/kg) i.v. and venti-
lated by means of a cuffed endotracheal tube attached
to a Harvard respirator. Seven animals underwent
acute surgical hypophysectomy via a midlipe approach
through the soft palate; these animals then received
intramuscular injections of hydrocortisone (10 mg)
and desoxycorticosterone acetate (DOCA) (1 mg).
In all dogs, polyethylene catheters were placed in each
ureter by means of subcostal flank incisions, and in 12
animals catheters were also placed in each renal vein.
Selected kidneys were denervated by stripping all
visible nerves and coating the renal pedicle with
absolute alcohol. In many animals, an adjustable
clamp was placed around the aorta above the renal
arteries in order to control renal perfusion pressure;
catheters placed in the brachial and femoral arteries
were used to monitor arterial pressure above and below
the clamp, respectively, using transducers (Statham
P23AC) attached to a direct-writing recorder (Grass
Instruments Co., Quincy, MA). After completion of
surgery, a constant infusion of normal saline was
started through a catheter in the femoral vein at
0.5 mi/mm; this solution contained sufficient inulin
and para-aminohippuric acid (PAH) to maintain
blood concentrations of these substances at approxi-
mately 25 and 1 mg/l00 ml, respectively. Experiments
were conducted under two protocols:
Group I: Effects of i.v. administration of clonidine in
intact animals. Urine was collected from 21 kidneys in
11 hydropenic, intact dogs before and after the i.v.
injection of clonidine (30 rig/kg of body wt). In four of
these animals (eight kidneys) clearances of inulin and
PAH were measured, and in six animals renal per-
fusion pressure (RPP) was controlled by means of the
aortic clamp. Observations were continued in all cases
for 90 mm, and in five experiments for 120 mm,
following the administration of the drug.
Group II: Effects of i.v. administration of clonidine in
acutely hypophysectomized dogs receiving a constant
infusion of A DH (vasopressin). In seven animals, a
constant infusion of ADH (aqueous Pitressin,
80 U/kg/min) in normal saline was started following
hypophysectomy. Adequacy of hypophysectomy in
these animals was demonstrated by the finding of
urine hypotonic to plasma from each dog prior to the
start of the ADH infusion. Renal clearance measure-
ments were made from 12 kidneys in these seven
animals; four kidneys were denervated. RPP was
controlled in five of these dogs. Measurements were
made before and after the injection of clonidine as
described above.
In all experiments, two to five control clearance
periods of 5 to 15 mm duration were made; arterial
and renal venous blood samples were obtained at the
midpoints of alternate periods. Following the injection
of clonidine, sequential 1 5-mm periods were obtained
for the duration of the experiment, with blood samples
in alternate periods. For purposes of statistical
analysis, values of two successive postdrug periods
were averaged and results expressed in 30-mm intervals
(0—30, 30—60, 60—90, 90—120) following clonidine
injection.
Blood samples were collected in chilled, heparinized
tubes, and centrifuged in the cold; plasma and urine
were analyzed for inulin by the anthrone method [13]
adapted for the autoanalyzer [14], and PAH by the
method of Harvey and Brothers [15]. Sodium and
potassium were measured by flame photometry
(Instrumentation Laboratories Model 343, Lexington,
MA) and osmolality by freezing point depression
(Advanced Instrument Corp., Needham Heights,
MA). Arterial hematocrit value was measured in
heparinized capillary tubes. Glomerular filtration rate
(GFR) was measured as the clearance of inulin, and
renal plasma flow (RPF) calculated from the clearance
and extraction (E) of PAH according to the formula
of Wolf [16]: RPF =V(U—R)/(A— R) where V urine
flow in mi/mm, and U, A and R are urine, arterial and
renal venous concentration of PAH, respectively.
Renal blood flow (RBF) was calculated as RBF=
RPF/1 — Hct, and renal vascular resistance (RVR) as
RVR RPP/RBF. Solute clearance (C0sm) was deter-
mined by the product of urine to plasma osmolality
ratio and V, and solute-free water reabsorption
(TCH2O) was calculated as C0 minus V. Filtration
fraction (FF) was determined as GFR/RPF. Student's
t test for paired data was used to test statistical
significance.
Results
Group I. Effects of i.v. admhiistration of clonidine in
intact dogs. Following i.v. injection of clonidine in a
dose of 30 pg/kg, there was an abrupt and marked
increase in blood pressure followed by a progressive
decline; on the average, arterial pressure had fallen
below the control value 60 to 90 mm following ad-
ministration of the drug (Table 1). A pronounced
bradycardia occurred following injection of the drug
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and persisted for the duration of the experiment.
Associated with these alterations in systemic hemo-
dynamics were consistent rises in hematocrit value and
plasma potassium concentration (Table 1); plasma
sodium concentration and osmolality were unaffected.
Clonidine also produced marked changes in renal
function. GFR fell slightly but significantly 60 to 90
mm after administration of the drug, and there was a
marked and sustained reduction in RPF which per-
sisted for the duration of the experiments (Table 2).
These changes were reflected in the accompanying
large increases in RVR and FF. The extraction of
PAH increased from 0.86 (sEM) to 0.91 0.01
30 to 60 mm after injection (P < 0.005). Sodium excretion
(UNaV) was decreased, and potassium excretion
(UKV) increased 30 to 60 mm after the drug was given
(Table 3). This increase in UKV may have been related
to the increased plasma potassium concentration,
since fractional potassium excretion (CK/Cjfl) did not
change in the eight kidneys in which it was measured.
The most consistent finding in these studies was an
increase in V, which occurred in 19 of the 21 kidneys.
This increase was due almost entirely to increased water
excretion, urinary osmolality (Usm) decreasing from
1378± 140 mOsm/kg of H20 to 448±82 (range: 116
to 1442) mOsm/kg of H20 30 to 60 mm after ad-
ministration of clonidine (P<0.OOl, Table 3, Fig. 1).
Intact Hypophysectomized
— 0.20L
I tControl 30 1,0 90 120 Control 30 60 90 120
Fig. 1. Effect of clonidine on urine osmolality (Uonm), urine flow
and free wafer reabsorption (TCH2O) in 21 kidneys from Ii
intact, hydropenic dogs and in 12 kidneys from 7 acutely hypo-
physectomized dogs receiving a constant infusion of ADH.
Clonidine injection (30 g/kg) is indicated by the broken lines.
Points represent mean SEM; results in the intact group at 90 to
120 mm are from only nine kidneys.
These reciprocal changes in V and Uosm following
clonidine injection were reflected in a decrease in
T°H20 from 0.66±0.05 to 0±0.12 mi/mm at 30 to 60
mm. This effect of the drug to promote renal water
excretion was transient; by 60 to 90 mm after ad-
ministration, V had fallen, and Usm had increased,
although both values remained significantly different
from the control observation (Table 3). In nine
kidneys of this group (five animals), collections were
continued up to 120 mm following drug injection.
At 60 to 90 mm, Uosm for these nine kidneys averaged
473 143 mOsm/kg of H20, and increased to 603 113
(range: 123 to 1517) mOsm/kg of H20 in the next
30-mm periol (P<0.05), further indicating that the
effects of the drug on water excretion were transient.
Overall, this tendency for U08m to increase late in the
experiments coincided with the peak hypotensive
effect of clonidine. However, in two experiments,
blood pressure remained at or above control levels for
the two hours following clonidine injection. U0.
from the kidneys of these animals remained depressed
and did not show the tendency to increase at the end of
the experiment that was exhibited by the group as a
whole.
In six denervated kidneys clonidine produced a
decrease in U0sm from 946 253 during control to
334±129 mOsm/kg of H20 at 30 to 60 min(P<0.01).
In six of the 11 animals, RPP was controlled by means
of the aortic clamp so that the acute hypertension pro-
duced by i.v. administration of clonidine was not
transmitted to the kidneys. U0sm in these 11 kidneys
fell from 1295±214 to 407 113 mOsm/kg of H2O
(P < 0.005) by 30 to60 mm following injection of the
drug. Solute clearance was not increased at any time
after the administration of clonidine. Thus, the en-
hanced water excretion caused by clonidine occurred
despite renal vasoconstriction and decreased UNaV
was present in denervated as well as innervated kidneys,
and was observed in the absence of increases in RPP,
GFR or solute excretion.
Group II: Effects of i.v. administration of clonidine in
acutely hypophysectomized dogs. The group of hypo-
physectomized animals had lower blood pressure,
GFR and rates of electrolyte excretion and solute
clearance during control measurements than the group
of intact animals (Tables I and 2). Infusion of ADH
produced a mean control of 952 (range: 532 to
1641) mOsm/kg of H20 in the 12 kidneys. Intravenous
injection of clonidine caused hemodynamic changes
similar to those observed in the intact group (Table 1);
by 30 to 60 mm following the injection, mean arterial
pressure had fallen to control levels, and by 90 to
120 mm it had fallen to 84±5 mm Hg, a value
significantly below the control value of 106±6 mm Hg
T
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Table 1. Effects of i.v. administration of clonidine on arterial pressure, heart rate,
BrachiaI artery p
mm Hg
ressure Heart rate
beats/mm
Ca 0—30 30—60 60—90 90—120 ca 0—30 30—60 60—90 90—120 Ca
Group P Intact hydropenia (N= 11)
Mean 128 142 121 112 113 138 95 97 95 — 44.1
SEM ±4 ±3 ±5 ±5 ±7 ±7 ±7 ±6 ±9 — ±2.0p <0.025 NS <0.05 NS <0.001 <0.001 <0.001
Group 11b Acute hypophysectomy with constant
Mean 106 136 103 89 84 142 88 93 96 97 43.4
SEM ±6 ±8 ±9 ±8 ±5 ±7 ±10 ±7 ±8 ±9 ±2.0
P <0.005 NS NS <0.02 <0.001 <0.001 <0.001 <0.001
a C= control period; subsequent columns refer to time (in minutes) after injection of clonidine.
b SEM= standard error of the mean, P= level of statistical significance (paired t test) compared with control value. NS = not significant
(P>0.05).
Table 2. Effects of i,v. administration of clonidine on renal
GFR
ml/mi,i
RPF
mi/mm
Cb 0—30 30—60 60—90 90—120 C1' 0—30 30—60 60—90 90—120
Group I
Mean
SEM
P
54.6
±5.3
62.2
±17.0
NS
52.7
±6.1
NS
46.0
±3.7
<0.005
54,3
±2.5
NS
Intact hydropenia (N= 8)
178 100 118 102 116
±22 ±17 ±18 ±7 ±9
<0.005 <0.005 <0.005 <0,001
Group II
Mean
SEM
P
21.1
±2.2
22.0
±2.1
NS
20.9
±2.2
NS
19.3
±2.1
NS
22.5
±3.2
NS
Acute hypophysectomy with constant infusion of
119 85 73 64 71
±17 ±9 ±10 ±9 ±9
<0,02 <0.001 <0.001 <0.01
a GFR = glomerular filtration rate, RPF = renal plasma flow, FF = filtration fraction, RVR = renal vascular resistance. Other abbrevia-
tions as in Table 1.
1' C= control period; subsequent columns refer to time (in minutes) after injection of clonidine.
Table 3. Effects of clonidine injection on
V Uosrn Cosm
mi/mm ,nOsm/kg of 1120 nil/mimi
C1' 0—30 30-60 60—90 90—120 C1' 0—30 30—60 60—90 90—120 C" 0—30 30—60 60—90
Group I IV. administered clonidine in intact
Mean 0.36 0.49 0.93 0.71 0.74 1378 991 448 608 603 1.02 1.02 0.93 0.87
SEM ±0.09 ±0.11 ±0.13 ±0.11 ±0.21 ±140 ±138 ±82 ±110 ±113 ±0.12 ±0.08 ±0.07 ±0.06
P <0.01 <0.001 <0.005 NS <0.001 <0.001 <0.001 <0.005 NS NS NS
Group II I.V. administered clonidine in hypophysectomized dogs receiving
Mean 0.19 0.18 0.16 0.14 0.14 952 938 871 987 1111 0.54 0.52 0.47 0.47
SEM ±0.03 ±0.02 ±0.01 ±0.01 ±0.02 ±88 ±94 ±46 ±51 ±62 ±0.07 ±0.05 ±0.05 ±0.05
P NS NS NS NS NS NS NS NS NS NS NS
a v= urine flow, Uo1'm= urine osmolality, Co,m= solute clearance, T'H20= free water reabsorption, UNV= sodium excretion, UKV=potas-
sium excretion. Other abbreviations as in Table 1.
bC=control period; subsequent columns refer to time (in minutes) after injection of clonidine.
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hematocrit value and plasma potassium concentration
Hematocrit Plas
vol %
ma potassium
mEq/liter
Plasma osmolality
mOsm/kg of H20
0—30 30—60 60—90 90—120 C0 0—30 30—60 60—90 90—120 C 0—30 30—60 60—90 90—120
50.8 51.6 51.1 49.0 3.6 4.1
<0.005 <0.005 <0.02 <0.05 <0.02
4J1 4.1 3,8 293
<0.01 <0.05 NS
292 293 294
NS NS NS
293
NS
infusion of vasopressin (n 7)
46.2 44.3 43.4 43.1 3.7 4.1
<0.025 NS NS NS <0.02
4.0 4.1 4.3 299
<0.01 <0.02 <0.05
300 298 297
NS NS NS
295
NS
hemodynamics in intact and hypophysectomized dogsa
FF RVR
mm Hg/mi/mm
C' 0—30 30—60 60—90 90—120 C' 0—30 30—60 60—90 90—120
0.33 0.53 0.46 0.45 0.48
<0.05 <0.001 <0.005 <0.001
0.455 0.710 0.579
NS <0.02
0.585 0.492
<0.02 <0.01
vasopressin (N= 12)
0.20 0.27 0.30 0.34 0.34
<0.001 <0.001 <0.005 <0.005
0.590 0.848 0.861
<0.01 <0.001
0.936 0.804
<0.005 <0.05
renal water and electrolyte excretion0
TCH2O UNOV UKV
mi/mm jEq/min Eq/min
90—120 Cb 0—30 30—60 60—90 90—120 C" 0—30 30—60 60—90 90—120 C' 0—30 30—60 60—90 90—120
hydropenic dogs (21 kidneys, 11 dogs)
0.68 0.66 0.54 0.01 0.16 —0.05 64.4 39.0 31.2 37.2 17.3 33.0 40.5 45.2 38.7 34.1
±0.05 ±0.05 ±0.11 ±0.12 ±0.12 ±0.20 ±15.2 ±7.0 ±6.7 ±9.2 ±5.3 ±2.9 ±4.0 ±5.0 ±3.0 ±5.3
NS NS <0.001 <0.001 <0.05 NS <0.05 NS NS <0.05 <0.05 NS NS
a constant infusion of vasopressin (12 kidneys, 7 dogs)
0.53 0.34 0.35 0.32 0.32 0.38 19.8 11.3 9.7 8.6 10.2 21.8 21.0 23.7 24.1 28.5
±0,07 ±0.05 ±0.04 ±0.04 ±0.04 ±0.05 ±7.8 ±4.0 ±2.7 ±2.6 ±2.9 ±2.0 ±2.0 ±2.9 ±3.2 ±4.2
NS NS NS NS NS NS NS NS NS NS NS NS NS
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(Table 1). Plasma potassium concentration and
hematocrit value were likewise increased by clonidine
(Table 1). No changes in plasma sodium concentration
or plasma osmolality were observed.
In addition to these systemic changes, clonidine
produced alterations in renal function which were
similar to those observed in the studies in intact
animals (Table 2). Changes in GFR were small but a
large fall in RPF was observed, in association with
rises in RVR and FF, and an increase in the renal
extraction of PAH (EPAH) from 0.83 0.03 to 0.87
(P<0.OOl). UaV fell slightly, although the
mean difference at 30 to 60 mm was not statistically
significant. In contrast to the findings in intact animals,
there was no increase in UKV following clonidine.
Clonidine failed to alter renal water excretion or
Uosm in the hypophysectomized dogs. V remained at
the control level after administration of the drug
(Fig. I, Table 3). Uosm was 871 46 mOsm/kg of
H20 at 30 to 60 mm after injection, the time period
when Uosm was maximally depressed in the group I
studies; this value was not significantly different from
the control value of 952 88 mOsm/kg of H20. There
were no changes in Cosm or TOH2O. This lack of effect
of clonidine on renal water excretion was not in-
fluenced by renal denervation and was the same in
kidneys in which RPP was maintained constant during
the transient hypertensive phase following drug in-
jection.
Discussion
The present studies confirm that i.v. administration
of clonidine increases V in anesthetized, hydropenic
dogs, and in addition show that this increased V is
associated with a decrease in U0 and TCH2O. Other
investigators reported increased V after clonidine
injection, but did not determine the mechanism
responsible for this effect [8—10]. In the present studies,
the increase in renal water excretion did not occur as a
result of increased RPP, since arterial pressure, after
an initial rise, was equal to or below control values 30
to 60 mm following injection of the drug, the time
period when V was highest and Uosm lowest. In
addition, control of RPP by an aortic clamp so that
the kidneys were not exposed to the initial hyper-
tensive effects of the drug did not alter this response.
GFR and solute excretion rates were either unchanged
or decreased following clonidine administration so
that these factors could not account for the enhanced
water excretion. These observations suggested, there-
fore, that the increased water excretion induced by
clonidine was not hemodynamically mediated, but
rather occurred as a result of central inhibition of
ADH release or through inhibition of the action of
ADH on the renal tubule.
To discriminate between those two possibilities,
studies were performed in acutely hypophysectomized
dogs with absent or markedly reduced sources of
endogenous ADH. These animals received a constant
infusion of ADH at a dose (80 iU/kg/min) shown in
other studies [11] to produce urine osmolalities com-
parable to those observed in intact hydropenic animals,
although less than that required to produce a maxi-
mally concentrated urine [7]. Renal function in these
animals was less than that observed in the intact
group, consistent with previous observations on the
effect of acute hypophysectomy on renal function
[18, 19]. The mechanisms responsible for this decrease
in renal function after hypophysectomy are not entirely
clear, although it has been demonstrated that adminis-
tration of growth hormone [20], adrenocorticotropic
hormone (ACTH) [21] or oxytocin [22] to the hypo-
physectomized animal will improve renal function.
The hypophysectomized dogs in the present study
received intramuscular injections of hydrocortisone
and DOCA which should have been large enough to
prevent any circulatory abnormality associated with
deficiency of either of these hormones. The two groups
of animals were otherwise treated identically.
In this group of hypophysectomized dogs receiving
a constant infusion of ADH, clonidine failed to in-
fluence the rate of water excretion. Uosm in this group
was comparable to, although slightly lower than, that
seen in the intact dogs, and failed to change after
clonidine injection even though the drug produced
similar effects on blood pressure and heart rate in the
two groups of animals. It is possible that the greater
increase in RVR noted in these hypophysectomized
dogs after clonidine administration could have masked
any tendency for the drug to alter V directly. This
does not seem likely, however, in view of the qualita-
tively similar changes in RVR seen in the intact group,
where effects on Uosm were pronounced. It thus seems
probable that the action of clonidine to increase renal
water excretion was due to inhibition of ADH release
rather than to antagonism of the action of ADH on the
renal tubule.
It is now well-established that a number of non-
osmotic stimuli influence the release of ADH [23].
Factors leading to decreased ADH secretion include
left atrial distention and increased activity of carotid
and aortic baroreceptors [24, 25], while cervical
vagotomy [25], carotid artery occlusion [25], hem-
orrhagic hypotension [26] and diminished blood
volume [27] all increase ADH release. The studies of
Schrier and his associates have extended and clarified
some of these phenomena [Il, 12, 28—30]. They have
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shown that a-adrenergic stimulation with norepine-
phrine infusions suppresses ADH release through an
indirect neural reflex pathway dependent on intact
carotid baroreceptors [11, 12]. Beta-adrenergic stimu-
lation with isoproterenol produces antidiuresis through
enhanced ADH release, via a mechanism related to the
systemic hypotension (and consequent altered baro-
receptor activity) resulting from isoproterenol adminis-
tration [28, 29]. Although other pathways could con-
ceivably be involved, the data most strongly suggest
that adrenergic stimulation modulates ADH secretion
through circulatory alterations which cause changes in
baroreceptor neural activity [12, 29]. In accord with
this hypothesis are the studies of Berl and Schrier
demonstrating that infusion of prostaglandin E1, a
compound without known adrenergic stimulating
properties, produced antidiuresis in conjunction with
systemic hypotension [30]. Thus, changes in carotid
arterial pressure caused by these pharmacological
agents lead to alterations in ADH secretion by altering
baroreceptor neural tone [12, 29].
The results of the present studies may best be
interpreted against this background. Clonidine is a
potent a-adrenergic agonist, producing cardiovascular
effects which mimic in part those of norepinephrine,
and which are prevented by the a-blocking agent
phentolamine [5, 31]. Thus, it is possible that the
acute hypertensive effects of clonidine altered baro-
receptor activity, and led to suppression of ADH
release, resulting in an increase in renal water ex-
cretion. Consistent with this suggestion is the finding
that Uosm, having reached a nadir 30 to 60 mm after
drug administration, then commenced to rise, and this
increase in Uosm was correlated with the peak hypo-
tensive action of clonidine. Thus, as hypotension
occurred, baroreceptor activity changed in an opposite
fashion to lead to enhanced secretion of ADH and
consequent antidiuresis (Table 3).
Support for this proposal is provided by observa-
tions in two experiments in which the hypotensive
action of clonidine was not manifested in the two-
hour study period. In these two experiments, U0
remained at a low level for the duration of the study,
showing no tendency to increase as was seen in other
experiments where hypotension did occur. Thus, over-
all, the effects of clonidine to suppress ADH release
can most readily be related to alterations produced in
carotid perfusion pressure, leading to changes in
baroreceptor activity.
These studies do not, however, rule out other
possible pathways. Clonidine is known to decrease
cardiac output primarily by a reduction in heart rate
[3, 4]; under these circumstances, left atrial pressure
could increase and, if it rose sufficiently, could lead
to decreased ADH release [24]. Alternatively, changes in
baroreceptor activity in the region of the aortic arch
[23, 25], or altered parasympathetic afferent tone
carried by the vagus nerve [25], could influence ADH
release. Finally, some other, as yet unmeasured, effect
of a-adrenergic stimulation by clonidine could lead to
suppression of ADH release. Regardless of which of
these possible mechanisms is operating, the present
findings are most consistent with the hypothesis that
clonidine suppresses the release of ADH indirectly as a
consequence of its potent effects on the circulation.
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